Wednesday, 3 March 2021 Biotechgate, the leading global biotech database, presents their annual Trend Analysis Report 2021 of the Dutch life sciences sector. The report shows the resilience of the Dutch biotech sector. Although the coronavirus had a negative impact on the amount of clinical trials, biotech companies attracted double the amount of venture … Continue reading Dutch Life Sciences Trend Analysis 2021 – Biotech Companies Show To Be Resilient And See Venture Financing Grow In 2020
Biotechgate presents the annual Trend Analysis Report 2020 for the Dutch life sciences sector. The report shows a stable number of life science companies and a sector which has grown in maturity. Biotech companies were successful in attracting venture capital; 2019 is a record year for venture financing.
With about 500 biotech companies registered, The Netherlands remain one of the strongest Life Science markets in Europe. The number of biotechs newly founded in 2018 was not as high as in previous years but the region is very far from stagnation. According to the data gathered in Biotechgate, over 100 million USD of venture … Continue reading Dutch Life Sciences Trend Analysis 2019
The life sciences industry remains very strong in the Netherlands. It currently consist of about 1000 companies, half of which belong to the biotechnology sector. The majority of products in companies’ pipelines are in the area of oncology, followed by the products indicated for infectious diseases. In 2017, there were 12 major financing rounds in … Continue reading Dutch Life Sciences Trend Analysis 2018
Our annual trend report for the Dutch life sciences market shows that the country remains an important centre of the industry. There were 14 major financing rounds in the biotech sector in 2016 for the total amount of 71 million USD. However, the number of newly founded companies was much lower in 2016 than in … Continue reading Dutch Life Sciences Trend Analysis 2017
While the first semester of 2015 was a quiet period, the second half of last year saw private Dutch biotech companies raise over USD 115m worth of funding in six rounds. Indeed it proved to be the largest financing period since the first semester of 2012. Dutch LS Trend Analysis 2016 Looking for your … Continue reading Dutch Life Sciences Trend Analysis 2016
3 Dutch companies, ProQR, UniQure and arGEN-X went public and raised approximately USD 272.5M combined. Nonetheless, the Biotech industry in the Netherlands has faced a drop in financing value of more than 50% whilst the number of rounds has decreased by 21%. The number of Biotech companies in the Netherlands has however increased significantly, from … Continue reading Dutch Life Sciences Trend Analysis 2015
With a strong finish in the second half of 2013, the Dutch, private biotechnology companies closed the year having amassed a total of USD 158m in venture financing. The strongest therapeutic areas, as represented by the biotech product pipeline (Therapeutics and Diagnostics), are those of Oncology (53 products in development), Infectious Diseases (36 products) and … Continue reading Dutch Life Sciences Trend Analysis 2014